# Trade Mark Journal No.2025/038 19 September 2025

## UK00004259806 5 September 2025 (10,41,42,44)

MYRIAD ONCOLOGY

International priority date claimed: 6 March 2025 (United States of America) (99070993)

Class 10
  Medical test kit related to oncology comprising specimen collection containers, printed instructions and test forms, materials for transmitting specimens, and printed user information inserts.
Class 41
  Providing online publications, namely, questionnaires for medical screening for diagnostic or treatment purposes.
Class 42
  Providing temporary use of non-downloadable software for use in medical screening for diagnostic or treatment purposes; Software as a service (SAAS) services featuring software for use in medical screening for diagnostic or treatment purposes.
Class 44
  Medical testing services related to oncology; genetic and genomic testing related to oncology; genetic testing for medical purposes; genetic testing services for diagnostic or treatment purposes; genetic counseling; medical diagnostic testing, monitoring, and reporting services; providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; diagnostic testing for the detection of cancer to assess the presence or absence of residual disease; health assessment services; providing personalized healthcare and medical information, namely, providing medical information and reports; providing medical information, consultancy and advisory services; health evaluation services, namely performing health assessments and health screening for purposes of determining medical risks and further testing.

Myriad Genetics, Inc.

Representative: HGF Limited